Pharmaxis Ltd buoyed by asthma study results
Australian pharmaceutical company Pharmaxis (ASX: PXS) today announced the successful completion of a Phase IIa dose profiling study with its new anti‐inflammatory agent ASM8 in patients with allergic asthma.
Pharmaxis’ chief executive offficer, Dr Alan Robertson said the clinical data demonstrated the potential value of this approach for treating asthma.
The moderate to severe sector of the asthma market, which is the target of ASM8, represents a significant commercial opportunity for Pharmaxis, and is under-served by current therapies.
The Pharmaxis study met the pre‐defined primary efficacy and safety endpoints and ASM8 was found to be safe at all doses tested and particularly effective at an inhaled dose of 8mg once per day.
ASM8 is the leading clinical‐stage asset in the portfolio of drug candidates acquired by Pharmaxis in its recent takeover of the Canadian company, Topigen Pharmaceuticals Inc.








